Cytokinetics (CYTK) Drops on $650-Million Debt Issuance
In a statement, Cytokinetics, Inc. (NASDAQ:CYTK) said it aimed to raise $650 million from the offer, an increase from the $550 million targeted initially.
Cytokinetics Inc (CYTK)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 11,747 | $645,615 | 0.31% | |
| 2. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.57 | 6,000 | $51,426.60 | 6,250 | 2019-11-19 | Filing | |
| $9.52 | 8,506 | $80,934.59 | 499,312 | 2019-12-11 | Filing | |
| $9.52 | 49,804 | $473,885.06 | 2,861,622 | 2019-12-11 | Filing | |
| $9.52 | 60,103 | $571,880.05 | 3,617,776 | 2019-12-11 | Filing | |
| $9.40 | 15,030 | $141,282.00 | 490,806 | 2019-12-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $58.22 | 2,105 | $122,553.10 | 140,610 | 2025-10-21 | Filing | |
| $60.03 | 5,000 | $300,150.00 | 363,108 | 2025-10-16 | Filing | |
| $60.56 | 2,000 | $121,120.00 | 140,610 | 2025-10-07 | Filing | |
| $60.00 | 6,757 | $405,420.00 | 9,778 | 2025-10-06 | Filing | |
| $55.05 | 5,000 | $275,250.00 | 368,108 | 2025-10-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 407,037 | $22,370,754 | 0.53% | |
| 2. | 197,367 | $10,847,290 | 1.54% | |
| 3. | 154,449 | $8,488,517 | 0.26% | |
| 4. | 82,460 | $4,532,002 | 0.86% | |
| 5. | 54,644 | $3,003,234 | 0% |
News See All
Cytokinetics (CYTK) Rockets 40.45% as Aficamten Results Promising
Cytokinetics snapped a two-day losing streak on Tuesday, soaring 40.45 percent to close at $49.62 apiece as investors cheered promising results from its study of Aficamten, its drug candidate for the ...
Citi Lowers Cytokinetics (CYTK) PT to $77 Due to Uneventful Q2 2025 Earnings
Cytokinetics Incorporated (NASDAQ:CYTK) is one of the best upside stocks to invest in now.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by. My name is Prilla, and I will be your conference operator today. Welcome to the Cytokinetics Q2 2025 Earnings Conference Call. This call is being recorded.
Cytokinetics to Present New Aficamten Data at ESC Congress 2025
Cytokinetics Incorporated (NASDAQ:CYTK) is one of the biotech stocks to buy according to Wall Street analysts.
10 Biotech Stocks to Buy According to Wall Street Analysts
On July 8, Jared Holz, Mizuho, joined 'Closing Bell Overtime' on CNBC to discuss if the biotech sector is ready for a breakout.
Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT
Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
13 Best Pharma Stocks to Buy According to Wall Street Analysts
On June 24, Jared Holz, Mizuho's healthcare strategist, appeared on CNBC's 'Fast Money' to talk about competition in the obesity drug space.
Cytokinetics Presents Positive Aficamten Data for Obstructive HCM at European Heart Failure Congress
Cytokinetics Incorporated (NASDAQ:CYTK) is one of the most active stocks to buy according to analysts.
11 Best Most Active Stocks To Buy According to Analysts
The Co-Chief Investment Strategist at John Hancock Investment Management, Emily Roland, believes that we're in a period of serious disinflation.
Hedge Fund Resource Center Billionaire Hedge Funds
